Fate Therapeutics Inc (NASDAQ:FATE)
| 2.12 Delayed Data As of Sep 29 |  -0.06 / -2.75%Today’s Change | 1.99 Today|||52-Week Range 23.96 | -78.99% Year-to-Date |
Largest transactions by value over
| Name | Type | Date | Shares traded | Share price | Transaction value | Since transaction |
|---|---|---|---|---|---|---|
Redmile Group Llc Director |  Sale | 4/14/2023 | 302,339 | $5.84 | $1.8M | -64.73% |
Redmile Group Llc Director |  Buy | 4/21/2023 | 256,639 | $6.18 | $1.6M | -65.92% |
Mendlein John D Director | Buy | 1/11/2023 | 88,048 | $5.67 | $499.2K | -62.94% |
Wolchko J Scott President & Chief Executive Officer | Sale | 1/10/2023 | 45,907 | $5.24 | $240.6K | -61.38% |
Mendlein John D Director | Buy | 1/13/2023 | 36,631 | $5.43 | $198.9K | -60.74% |
Redmile Group Llc Director | Buy | 4/14/2023 | 25,700 | $6.00 | $154.2K | -64.73% |
Redmile Group Llc Director | Buy | 4/20/2023 | 20,000 | $5.99 | $119.8K | -64.67% |
Tahl Cindy R Secretary & General Counsel | Sale | 1/10/2023 | 11,553 | $5.24 | $60.5K | -61.38% |
Valamehr Bahram Chief Research & Development Officer | Sale | 1/10/2023 | 10,917 | $5.24 | $57.2K | -61.38% |
Chu Yu Waye Chief Medical Officer | Sale | 1/10/2023 | 7,825 | $5.24 | $41.0K | -61.38% |
Page of 2